Publications by authors named "Nikolay Cherkezov"

3 Publications

  • Page 1 of 1

Increased Serum Pentraxin 3 Is Associated with Prediabetes and Type 2 Diabetes in Obese Patients with Nonalcoholic Fatty Liver Disease.

Metab Syndr Relat Disord 2021 Nov 24. Epub 2021 Nov 24.

Department of Internal Medicine, Clinic of Endocrinology and Metabolic Disease, University Hospital "Alexandrovska," Medical University Sofia, Sofia, Bulgaria.

Pentraxin 3 (PTX3) is an acute-phase protein, which resembles C-reactive protein in both structure and function, and belongs to the same family. PTX3 is associated with cardiovascular diseases, obesity, and metabolic syndrome (MetS). This study evaluated the relationship between serum PTX3 levels, prediabetes, newly diagnosed type 2 diabetes mellitus (T2DM), and other biochemical and clinical parameters in obese patients with nonalcoholic fatty liver disease (NAFLD). A total of 77 obese patients with NAFLD were included. Forty-seven of them were with normal glucose levels and 30 were with glycemic disorders, including prediabetes and newly diagnosed T2DM. Serum PTX3 was measured using ELISA method. Higher PTX3 serum levels were found in patients with prediabetes and T2DM compared with those with normal blood glucose (2321.29 ± 926.63 vs. 1877.03 ± 895.45 pg/mL,  = 0.028). There were significant correlations between PTX3 and alanine aminotransferase ( = 0.018), gamma-glutamyl transferase ( = 0.005), and neuropathy disability score ( < 0.05). The presence of hypertension, dyslipidemia, insulin resistance, and MetS, as well as the number of components of the MetS did not affect PTX3 levels. PTX3 serum levels were higher in an obese subject with NAFLD with prediabetes and T2DM.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1089/met.2021.0086DOI Listing
November 2021

Lumican in Obese Patients with Nonalcoholic Fatty Liver Disease With or Without Prediabetes.

Metab Syndr Relat Disord 2020 11 11;18(9):443-448. Epub 2020 Aug 11.

Department of Internal Medicine, Clinic of Endocrinology and Metabolic Diseases, University Hospital "Alexandrovska," Medical University, Sofia, Bulgaria.

Lumican is a small leucine-rich proteoglycan that regulates the assembly of collagen fibers in the extracellular matrix of different tissues. Excess collagen production in the liver is key in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and might contribute to the risk of type 2 diabetes mellitus and cardiovascular diseases. The aim of this study was to evaluate the relationship between serum lumican and prediabetes, and other biochemical and clinical parameters in obese subjects with NAFLD. The study group included 79 subjects with obesity and NAFLD of which 41 had normal carbohydrate tolerance and 38 had prediabetes. Serum lumican was measured by means of enzyme-linked immunosorbent assay. Higher lumican serum levels were found in patients with prediabetes compared with those with normal carbohydrate tolerance (0.117 ± 0.074 vs. 0.080 ± 0.048 ng/mL,  = 0.010) as well as in subjects with metabolic syndrome (MetS) versus those without MetS (0.113 ± 0.071 vs. 0.079 ± 0.048 ng/mL,  = 0.034). There was also a modest positive association between lumican levels and fasting glucose ( = 0.228,  < 0.05). Lumican levels ≥0.07 ng/mL determine a 3.9-fold higher risk of prediabetes (odds ratio: 3.945, 95% confidence interval: 1.518-10.254,  = 0.005). Lumican levels were higher in obese subjects with NAFLD with prediabetes and MetS. Lumican bears an increased risk for prediabetes in the study population.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1089/met.2020.0001DOI Listing
November 2020

The association between retinol-binding protein 4 and prediabetes in obese patients with nonalcoholic fatty liver disease.

Arch Physiol Biochem 2019 Oct 7:1-6. Epub 2019 Oct 7.

Department of Internal Medicine, Clinic of Gastroenterology, University Hospital "St. Ivan Rilski", Medical University - Sofia , Sofia , Bulgaria.

Retinol-binding protein 4 RBP4) is associated with visceral fat and insulin resistance (IR) in obesity, type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD), but some of these data remain controversial. This study evaluated the relationship between serum RBP4 levels and prediabetes in obese patients with NAFLD. A total of 79 obese NAFLD patients without ( = 41) and with prediabetes ( = 38) were included. Serum RBP4 was measured using ELISA method. Higher RBP4 serum levels were observed in patients with prediabetes, metabolic syndrome (MetS), or dyslipidaemia. There was correlation between RBP4 levels and visceral adiposity index (VAI), glucose, insulin, HOMA-IR, and Quicki index. RBP4 ≥ 61 mcg/ml have about 3.5-fold higher risk of prediabetes (OR 3.544, 95% CI 1.385-9.072, =.008), and RBP4 ≥ 55 mcg/ml increased the risk for MetS approximately 3.1 times. RBP4 is associated with increased risk for prediabetes and MetS in obese patients with NAFLD.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/13813455.2019.1673429DOI Listing
October 2019
-->